Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
about
Gene therapy for brain tumors: basic developments and clinical implementationDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsHMGB1 mediates endogenous TLR2 activation and brain tumor regressionGene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelStudy of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyCurrent status of gene therapy for brain tumors.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Recent developments on immunotherapy for brain cancer.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelPresent trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.Klotho regulates postnatal neurogenesis and protects against age-related spatial memory loss.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.Gene therapy and targeted toxins for glioma
P2860
Q26829086-ABFC77B4-11F4-4924-9C5A-56C621C437E0Q27014829-48B7044D-9DB2-41C8-BFCB-2ED5DE37FCC8Q27307459-39AB255B-C2B5-4D48-B138-FC41366E13C7Q33828114-C34AF3BB-8F60-4914-AEA2-EFFC18DB5A50Q33877450-EC3560E9-7596-45C0-BF67-2940A54AAD8AQ33924763-E09EACF8-4B4B-4566-88F8-9E6D3678615BQ34012284-4391A875-742A-4877-8A34-69061B05733DQ34069598-419D71EB-AB7D-4C77-8CAF-9F389791B6BAQ34318157-BDB14B6D-2F62-447F-B430-8E10D033E8ADQ35285859-9926947E-2569-4027-9F30-24403C39AACFQ35527165-C207F1F7-CA62-42D1-90FF-3ED0F881CED3Q35992355-7956F136-B114-414B-850F-609CD3F45A47Q36200438-880BA9D9-9D19-4FA6-9B59-5A8882496867Q36534329-4CDB14C9-CDC3-4EE6-91F6-04D1A753A372Q36540199-6DDEFE1C-9698-4B29-9DBE-3C5C6C9DE362Q36811505-AE96822A-76A1-4026-B4C8-240DCD0E2FD8Q37050094-5E1EA2AE-D652-492A-A2C5-1F02A7772218Q37160479-DE55099D-1720-479E-9691-4890177F34EFQ37403279-1B3AD684-1A7B-4FB8-97F3-3B2A6F52961FQ37804933-AEC43B94-277D-4F35-828E-63AB3AF00084Q38609968-2F4430B8-F01C-4AD7-8CA1-2BF63657432DQ38752688-C202046A-49EC-423A-BA47-FBD20E66AECFQ39607848-809AF46F-9C89-4C1A-BF80-62389CAA84DCQ41189810-C8AF43D0-A176-4316-8075-672A8A448EEEQ47227033-C63C0171-870A-4A04-A67F-4B36F9744B24Q47318878-7BE3D6B8-4283-4446-8683-91F80E5F01D7Q51847569-67C85E3E-80E6-4B92-A4AE-CAD6826B6526Q57006162-03EBEEE8-0BE5-4BC5-AD34-C0A4237547EC
P2860
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Flt3L in combination with HSV1 ...... r-induced behavioral deficits.
@en
type
label
Flt3L in combination with HSV1 ...... r-induced behavioral deficits.
@en
prefLabel
Flt3L in combination with HSV1 ...... r-induced behavioral deficits.
@en
P2093
P2860
P356
P1433
P1476
Flt3L in combination with HSV1 ...... or-induced behavioral deficits
@en
P2093
A K M Ghulam Muhammad
Catherine J Bresee
Charlene M Manalo
Chunyan Liu
Gwendalyn D King
Kurt M Kroeger
Marianela Candolfi
Pedro R Lowenstein
Robert N Pechnick
P2860
P304
P356
10.1038/MT.2008.18
P577
2008-02-19T00:00:00Z